For the roughly 100,000 Americans living with sickle cell disease — most of them Black — pain has long been understood as a predictable consequence of misshapen blood cells starving tissues of oxygen. A small but striking pilot study from Rutgers now suggests that the biology of that pain may be stranger and more layered than assumed: not the proteins long suspected of driving suffering, but those governing cellular energy and nerve maintenance, appear to separate those in high pain from those in low. It is an early signal, not yet a map, but it points toward unexplored territory in one of med
Blood protein patterns may reveal pain drivers in sickle cell disease
Sickle cell disease affects approximately 100,000 Americans, predominantly non-Hispanic Black populations, causing severe pain episodes and organ damage.
The pain may not follow the pathway researchers long assumed
Mark
So they found that people with high pain and low pain have the same levels of pain-driving proteins. That seems backwards—shouldn't more pain protein mean more pain?
Mimi
That's exactly what makes this interesting. It suggests the pain isn't coming from the usual suspect. The differences showed up in proteins related to energy production and cellular maintenance instead.
Luke
But we should be careful here. This is sixteen people, one blood draw each. We don't know if these protein patterns actually cause the pain differences or if they're just along for the ride.
Mark
What would it take to know that?
Mimi
Larger studies over time, combined with brain imaging and cognitive testing. They need to see if the protein patterns predict changes in pain or neurological health.
Luke
Right. And even then, you're measuring proteins in blood platelets, not directly in the nervous system where pain actually happens. It's a proxy.
Mark
So this is really just the beginning of something?
Mimi
Exactly. It's a signal that the biology of pain in sickle cell disease might be more complicated than we thought. But it's not a treatment or a diagnostic test yet.
Luke
The honest version is: we found something unexpected in a small group. We don't know what it means. But it's worth investigating further.
Mark
And if they do find something, could it help people who are suffering right now?
Mimi
Eventually, yes. But that's years away. First you have to understand what's actually happening in the body.
Der Puls
- Sickle cell disease condemns tens of thousands to unpredictable, severe pain episodes, yet science has struggled to explain why suffering varies so dramatically between patients sharing the same genetic mutation.
- A Rutgers pilot study of just sixteen adults upended a core assumption: the proteins long believed to drive pain were equally present in both high- and low-pain patients, offering no explanation for the difference.
- What did differ were proteins tied to mitochondrial energy production, cellular maintenance, and neurodegeneration — biological processes no one had centered in the conversation about sickle cell pain.
- The findings are preliminary and constrained — a single blood draw, no healthy comparison group, no direct brain measurements — leaving causality entirely unresolved.
- Researchers are now calling for larger, longitudinal studies pairing protein analysis with brain imaging and cognitive assessments to determine whether these patterns can become diagnostic or therapeutic tools.
For the roughly 100,000 Americans living with sickle cell disease — most of them Black — pain has long been understood as a predictable consequence of misshapen blood cells starving tissues of oxygen. A small but striking pilot study from Rutgers now suggests that the biology of that pain may be stranger and more layered than assumed: not the proteins long suspected of driving suffering, but those governing cellular energy and nerve maintenance, appear to separate those in high pain from those in low. It is an early signal, not yet a map, but it points toward unexplored territory in one of medicine's most persistent and inequitable burdens.
Researchers at Rutgers have uncovered something unexpected in the blood of sickle cell patients: those reporting high pain and those reporting low pain carry nearly identical levels of the proteins long thought to drive that suffering. The real differences lie elsewhere — in proteins governing how cells generate energy, maintain themselves, and clear away damage. Some of those same proteins are also linked to nerve cell injury, hinting at a neurological dimension to sickle cell pain that has gone largely unexamined.
Sickle cell disease reshapes red blood cells into rigid, crescent forms that block blood vessels and deprive tissues of oxygen. It affects roughly 100,000 Americans — about nine in ten of them Black — producing episodes of severe pain, chronic disability, and lasting organ damage. Why pain intensity varies so widely between patients with the same underlying mutation has remained one of the disease's enduring mysteries. Lead author Keesha Powell-Roach, an assistant professor at the Rutgers School of Nursing, suspected the answer might not lie where researchers had been looking.
The team recruited sixteen adults from a sickle cell clinic in Memphis, Tennessee. All lived with chronic pain, though half reported lower pain levels at the time of their visit. Blood samples were drawn, and researchers examined platelets — cells central to clotting and inflammation — identifying 4,196 distinct proteins. The comparison between high- and low-pain groups revealed differences concentrated not in pain-signaling pathways, but in mitochondrial and cellular housekeeping functions.
Powell-Roach was careful about the limits of what sixteen participants and a single blood draw can show. The study cannot establish whether these protein patterns cause pain, result from it, or simply reflect the disease's broader progression. There is no healthy comparison group, and no direct measurement of brain health was included. "It's too early to make any broad statements," she said, while affirming that the findings justify serious follow-up.
What comes next, the team hopes, are larger studies tracking patients over time and pairing protein measurements with brain imaging and cognitive assessments. Only then could researchers determine whether these biological signals reliably predict pain or neurological decline — and whether they might eventually guide new treatments. For now, the study stands as a reminder that the mechanisms behind sickle cell pain may be more complex than current models allow, and that relief may require looking beyond the usual suspects.
Researchers at Rutgers have identified an unexpected pattern in the blood of people with sickle cell disease: those reporting high levels of pain and those reporting low levels show nearly identical amounts of a protein known to trigger pain in other conditions. Yet their blood tells a different story in other ways. A pilot study of sixteen adults found striking differences in proteins tied to how cells produce energy, maintain themselves, and clear away damaged components. The discovery suggests that the pain some sickle cell patients endure may not follow the same biological pathway researchers have long assumed.
Sickle cell disease warps red blood cells into rigid, sickle-shaped forms that jam up blood vessels and starve tissues of oxygen. The result is a disease that strikes roughly 100,000 Americans—about nine in ten of them Black—and brings episodes of severe pain, chronic suffering, and permanent damage to organs. For decades, researchers have worked to understand why pain varies so dramatically from person to person, even among those with the same genetic mutation. Keesha Powell-Roach, an assistant professor at the Rutgers School of Nursing and lead author of the study, suspected the answer might lie not in the proteins everyone assumed were driving pain, but somewhere else entirely.
The team recruited participants at the sickle cell clinic at Regional One Health in Memphis, Tennessee. All sixteen adults lived with chronic pain, though eight reported experiencing lower pain levels at the time of the study visit. Each person filled out pain questionnaires and gave blood samples. The researchers then examined platelets—the blood cells responsible for clotting and inflammation—and identified 4,196 distinct proteins within those samples. When they compared which proteins appeared at higher or lower levels between the high-pain and low-pain groups, a pattern emerged that surprised them.
The proteins that differed between the two groups had little to do with pain itself. Instead, the variations involved proteins that govern mitochondrial function—the cellular structures that generate usable energy—as well as proteins involved in maintaining and removing damaged cellular components. Some of these same altered proteins can also contribute to nerve cell damage, suggesting a possible link to the neurological complications that sickle cell disease can cause over time. Powell-Roach emphasized the limits of what this small pilot could show. "It's too early to make any broad statements," she said. "But these findings do justify a wide range of follow-up investigations to figure out why we found these differences and whether they indicate potential strategies to reduce pain or create new treatments."
The study carries real constraints. Sixteen people is a small group. The blood samples were taken at a single moment in time, making it impossible to know whether the protein differences cause pain, result from it, or simply reflect other aspects of how the disease progresses. The researchers did not directly measure brain injury or cognitive decline, and they had no comparison group of people without sickle cell disease to establish what normal looks like. The findings do not yet constitute a diagnostic test or point to a specific new treatment.
What they do offer is a direction. Powell-Roach and her team, many of whom came from the University of Tennessee, are calling for larger studies that follow patients over months or years, combining protein measurements with cognitive assessments and brain imaging. Those studies would test whether the blood protein patterns actually predict changes in pain or neurological health—a necessary step before researchers could turn these biological observations into tools that clinicians could use. Until then, this pilot remains what it is: a signal that the mechanisms driving pain in sickle cell disease may be more complex and more varied than current understanding suggests, and that looking beyond the usual suspects in the blood might reveal new paths toward relief.
Bemerkenswerte Zitate
These findings justify a wide range of follow-up investigations to figure out why we found these differences and whether they indicate potential strategies to reduce pain or create new treatments.— Keesha Powell-Roach, Assistant Professor, Rutgers School of Nursing
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical ↗
Health & Medicine